The purpose of these studies will be to identify and validate clinical biomarkers and predictive algorithms for disease prognosis and therapeutic response.
Under the agreement, Monogram and Dana-Farber will jointly conduct experiments employing eTag assays to investigate the relationship between signaling pathway activation and clinical responsiveness to targeted drugs in a variety of important cancers. Monogram will have rights to diagnostic and predictive medicine applications of all resulting inventions.
“We believe that our eTag technology may open up a completely new approach to the management of serious diseases. The collaboration with the world class researchers at Dana-Farber will help us in our mission to match the right drug to the right patient at the right time,” stated William Young, CEO of Monogram.